Real World Applicability of Obeticholic Acid for Primary Biliary Cholangitis

Change in proportion of beta7 positive CD4+ and CD8+ T-cells in peripheral blood in PSC-IBD patients after treatment with vedolizumab, as measured by flow cytometry.Mean time points post-vedo are 1: 40.4 days (range 14-123); 2: 115 days (42-260); 137.5 days (95-180).The reduction in proportion of beta7+ cells was significant to timepoint 1 in both CD4+ and CD8+ populations.The left-hand graphs show individual patients joined as lines, whereas the right-hand graphs show the same data expressed as mean and standard deviation.Top row -CD4+ T-cells; bottom row: CD8+ T-cells.